Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cohen, Joshua
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
IMGN151-1001, NCT05527184: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers	Recruiting	1	423	US	IMGN151	AbbVie	Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer	02/27	02/27
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors	Recruiting	1	410	Europe, US, RoW	CLN-619, Pembrolizumab	Cullinan Therapeutics Inc.	Advanced Solid Tumor	03/26	06/26
CAMPUS-E, NCT04493736: CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"	Recruiting	N/A	2000	US	MHSAFE app recording	Clarigent Health	Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation, Depression, Anxiety, Aggression, Trauma, Psychological	09/24	09/24
Namiranian, Sonali
No trials found